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Background: Infections in hemodialysis (HD) patients lead to high morbidity and mortality rates and are
associated with early cardiovascular mortality, possibly related to chronic inflammation. Intravenous (IV) iron is
widely administered to HD patients and has been associated with increased oxidative stress and dysfunctional
cellular immunity. The purpose of this study was to examine the effect of three commercially available IV iron
preparations on intracellular reactive oxygen species generation and lymphocyte subpopulation survival.
Methods: Peripheral blood mononuclear cells (PBMC) were isolated from healthy donor buffy coat. PBMC were
cultured and incubated with 100 μg/mL of sodium ferric gluconate (SFG), iron sucrose (IS) or iron dextran (ID) for
24 hours. Cells were then probed for reactive oxygen species (ROS) with dichlorofluorescein-diacetate. In separate
studies, isolated PBMCs were incubated with the 25, 50 or 100 μg/mL iron concentrations for 72 hours and then
stained with fluorescein conjugated monoclonal antibodies for lymphocyte subpopulation identification. Untreated
PBMCs at 24 hours and 72 hours served as controls for each experiment.
Results: All three IV iron preparations induced time dependent increases in intracellular ROS with SFG and IS
having a greater maximal effect than ID. The CD4+ lymphocytes were most affected by IV iron exposure, with
statistically significant reduction in survival after incubation with all three doses (10, 25 and 100 μg/mL) of SFG, IS
and ID.
Conclusion: These data indicate IV iron products induce differential deleterious effects on CD4+ and CD16+
human lymphocytes cell populations that may be mediated by intracellular reactive oxygen species generation.
Further studies are warranted to determine the potential clinical relevance of these findings.
Background
Infection is the second leading cause of mortality among
hemodialysis (HD) patients. Infections in HD patients
are also associated with increased cardiovascular mortal-
ity, which may be related to immune system dysfunction
resulting in recurrent infections that contribute to
chronic inflammation and accelerated atherosclerosis
[1]. Cellular dysfunction of both innate (e.g. T cells and
macrophages) and adaptive (e.g. B cells) immunity is
well described in patients with chronic kidney disease
(CKD) and may be attributable to many factors includ-
ing accumulated uremic toxin burden, bio-incompatible
dialysis membranes, anemia, malnutrition and altered
iron metabolism [1,2].
Transfusional iron overload has long been linked with
immune dysfunction including defective neutrophil and
macrophage chemotaxis and phagocytic activity as well
as decreased natural killer (NK) cell activity [3]. Intrave-
nous (IV) iron compounds, including iron sucrose and
iron dextran, which are widely administered to HD
patients, have been associated with depressed neutrophil
intracellular killing capacity, reduced polymorphonuclear
cell hydrogen peroxide production and impaired phago-
cytic activity [4,5]. More recently, HD patients were
noted to have T cell and NK cell proliferation defects
compared to normal control populations; however,
potential relationships to IV iron administration were
not explored in these studies [6,7]. Poor immune
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any medium, provided the original work is properly cited.response to vaccination corroborates the theory of T cell
dysfunction in HD patients. IV iron administration was
reported to be associated with lower post-vaccination
HBsAg titers compared to patients not exposed to IV
iron [8]. Clearly, more data are needed to understand
the impact of IV iron on immune function in HD
patients who are at high risk of infections with subse-
quent poor outcomes. There are currently several com-
mercially available IV iron products in the United
States, including iron dextran (INFeD®), sodium ferric
gluconate (Ferrlecit®), and iron sucrose (Venofer®). Dif-
ferences exist between the compounds with regard to
molecular weight of the iron-carbohydrate group, stabi-
lity of the iron-carbohydrate complex, and the rapidity
with which iron is released from the iron-carbohydrate
complex[9]. We have previously shown that the smaller
molecular weight iron-carbohydrate complexes (sodium
ferric gluconate and iron sucrose) are associated with
greater appearance of free, or non-transferrin-bound,
iron in vivo when compared to the larger molecular
weight iron-carbohydrate complex, iron dextran [10].
There have been no comparative studies examining the
effect of IV iron exposure on lymphocyte proliferation and
subpopulation survival. The purpose of this translational
in vitro study was to examine the effects of the three com-
mercially available IV iron compounds on intracellular
oxidative stress and survival of human lymphocytes.
Methods
PBMC Isolation
Peripheral blood mononuclear cells (PBMCs) from
healthy blood donor buffy coat were separated from
10 mL of whole blood on Ficoll-Hypaque density gradi-
ents, washed twice in phosphate buffered saline (PBS)
(pH 7.4), and centrifuged again at 1500 × g and 4°C.
Isolated PBMCs were cultured in RPMI-1640 medium
supplemented with 10% heat inactivated human AB
serum (Mediatech Inc, Manassas VA), 100 U/mL peni-
cillin, 100 μg/mL streptomycin, and 2 mM L-glutamine
(Omega Scientific Inc, Tarzana CA) at 37°C at 5% CO2
(Excella Eco-170, New Brunswick Scientific, Edison, NJ).
Reactive Oxygen Species (ROS) Detection
Intracellular oxidative stress was measured by fluores-
cent probe, dichlorofluorescein. Briefly, PBMCs were
isolated from healthy volunteers, plated onto 96-well
plates, and treated with phytohemagglutinin (PHA). The
cells were treated for 2, 4, 8 and 24 hours with 100 μg/
mL concentrations of IV iron agents Iron Dextran (ID)
(INFeD®, Watson Pharma, Inc, Morristown, NJ), Iron
Sucrose (IS) (Venofer®, American Regent, Shirley, NY)
and Sodium Ferric Gluconate (SFG) (Ferrlecit®, Watson
Pharma, Inc, Morristown, NJ). Untreated PBMCs ana-
lyzed at 24 hours served as controls and experiments
were performed in triplicate. Cells were washed with
Krebs-Ringer buffer and subsequently incubated in Dul-
becco’s modified essential medium containing 100 μM
Dichlorofluorescein-diacetate (DCFH-DA) and 1% fetal
bovine serum in 5% CO2 and 95% air at 37°C. One hour
later, DCFH-DA was removed, and cells were washed
with Krebs-Ringer buffer. Fluorescence was measured in
a fluorescent plate reader (Spectra Max Gemini XS,
Molecular Devices Sunnyvale, CA) with the temperature
maintained at 37°C.
Lymphocyte Subpopulation Analysis
PBMCs from healthy volunteers were stimulated with IV
iron agents SFG, IS, and ID for 72 hours at concentrations
of 10, 25, and 100 μg/mL. The PBMCs were then stained
with fluorescein conjugated monoclonal antibodies and
quantified by flow cytometry (BD FACS Scan (Becton
Dickinson, BD Biosciences, San Jose, CA) and CellQuest
Pro Version 5.2 (Rockville, MD) to assess the proportion
of T helper (CD4




+) and B cell (CD40
+) subpopulations
among the viable cells. Untreated PBMCs served as con-
trols and experiments were performed in duplicate.
Statistics
A two-way analysis of variance (ANOVA) was used to
compare values among the treatments. Post hoc multi-
ple-comparison test with a Bonferroni (parametric-equal
variance) test was done to determine significant differ-
ences among the groups. A Student’s t-test was per-
formed to determine significance between individual
treatments.
Results
Intracellular Reactive Oxygen Species Generation
Incubation with 100 μg/mL IS induced significantly
higher ROS generation compared to control at 8 and
24 hours. (Figure 1) Incubation with SFG induced signif-
icantly higher ROS generation at 8 hours than controls.
ID treatment at all time points was not associated with
any significant difference in ROS generation versus con-
trol. SFG and IS appeared to increase intracellular ROS
in a time-dependent manner. At 8 hours, a 66% increase
from control was measured after incubation with SFG
and a 60% increase from control experiments was mea-
sured after incubation with IS. The peak mean fluores-
cence index (MFI) for ID, occurring at 4 hours, showed
a 48% increase versus control.




+ populations were in gen-




impacted by all three IV iron preparations at all three
Gupta et al. BMC Nephrology 2010, 11:16
http://www.biomedcentral.com/1471-2369/11/16
Page 2 of 5doses (10, 25, 100 μg/mL, Figure 2). At the 10 and
25 μg/mL dose, SFG decreased the CD4
+ population
more than the other IV iron agents (p < 0.05). However,
IS at 100 μg/mL caused the largest percentage decrease
in the CD4
+ population with a 68% reduction at
72 hours (p < 0.05). All three IV iron drug preparations
decreased the CD4
+ population in a dose dependent
manner. Survival of the CD16
+ population was reduced
more by SFG than by ID and IS, respectively.
Discussion
Iron is a vital metal for the proliferation and survival of
all cells including those of the immune system. Iron
deficiency causes a profound reduction in peripheral T
cells and atrophy of the thymus. Conversely, iron over-
load as a result of transfusions in thalassemia is asso-
ciated with decreases in circulating CD4+ T
lymphocytes while expansion of CD8+CD28- T lympho-
cytes has been associated with iron overload in hemo-
chromatosis. Oversaturation of transferrin above 100%
and presence of non-transferrin-bound iron is associated
with enhanced uptake of iron by lymphocytes and inhi-
bition of lymphocyte proliferation [11]. In vitro exposure
of PBMC to ferric citrate has been shown to specifically
inhibit E-rosette formation, a marker of T cell presence
and CD2 expression [12].
Figure 1 Data are presented as mean ± SD change in MFI for iron dextran (ID), iron sucrose (IS) and sodium ferric gluconate (SFG)
versus control at 2, 4, 8 and 24 hours. *p < 0.05 vs. control. Controls represent untreated cells for each individual iron product experiments.
Figure 2 Data are presented as mean percent reduction in MFI versus control. For CD4+ *p < 0.05 all iron doses vs. control. For CD16+
+p
< 0.05 all iron products at 100 μg/mL vs. control, **ID 100 μg/mL vs. SFG 100 μg/mL, and
++SFG 100 μg/mL vs. IS 100 μg/mL. ID = iron dextran,
IS = iron sucrose and SFG = sodium ferric gluconate.
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complexes are routinely used in HD patients and are
associated with the presence of free, or non-transferrin-
bound, iron. Furthermore, infection, especially related to
vascular access, continues to be a monumental problem
in HD patients and is associated with high morbidity
and mortality rates, costly hospitalizations and treat-
ments, and has recently been associated with cardiovas-
cular disease [13]. Patients with chronic kidney disease
a r ei m m u n o s u p p r e s s e da n dt h ee t i o l o g yo fi m p a i r e d
immunity is likely multifactorial possibly related to
depletion of cell subsets as well as dysfunctional cell
function (e.g. chemotaxis). IV iron is widely adminis-
tered to HD patients and has been shown in several pre-
vious studies to adversely affect immune cell
proliferation and function[4,5]. This study is the first, to
our knowledge, that compares the effects of three com-
mercially available IV iron preparations on intracellular
immune cell ROS generation and survival.
This study indicates that all of the IV iron prepara-
tions are associated with increased intracellular ROS
generation and reduced lymphocyte survival particularly
of the CD4
+ and CD16
+ cell subpopulations. Interest-
ingly, the smaller molecular weight IV iron compounds
induced greater intracellular ROS generation, consistent
with previous data regarding the appearance of non-
transferrin-bound iron, which is the inciting factor driv-
ing the Fenton-Haber Weiss reaction [9,10]. These data
imply that immune cell oxidative stress and reduced
proliferation may be related to the molecular weight and
stability of the IV iron products. Intracellular oxidative
stress peaked between 8 and 24 hours which suggests
that there is a lag time between administration of IV
iron and potential toxicity. Thus, understanding the
kinetic profile of intracellular ROS generation is impor-
tant when examining these interactions in vivo[14].
Increased intracellular oxidative stress may predispose
cells including lymphocytes to membrane destabilization
(e.g. lysosomal and mitochondrial) and subsequent
apoptosis. Tenopoulou et al. studied Jurkat cells, an
immortalized T lymphocyte cell line, under conditions
of continuous intracellular exposure to hydrogen perox-
ide [15]. A series of well-designed experiments examin-
ing the effects of iron compartmentalization,
demonstrated that redox active iron released from
unstable lysosomes resulted in nuclear DNA damage,
mitochondrial membrane potential instability, and apop-
tosis. These effects were not observed when cells were
incubated with the iron chelator, desferoxamine, which
has been shown to be endocytosed and reach the lysoso-
mal compartment. Studies examining the relationship
b e t w e e nI Vi r o na d m i n i s t r a t ion and alteration of intra-
cellular iron metabolism are limited. However, Zager
et al. observed gross uptake of iron after human
proximal tubule cell incubation with iron sucrose and
sodium ferric gluconate but this effect was not observed
with iron dextran [16]. Intracellular iron incorporation
with each IV iron compound was also confirmed by
electron microscopy. Thus, it is biologically plausible
that IV iron may alter the intracellular labile iron pool
and H2O2-catabolizing intracellular antioxidant systems
(e.g. glutathione reductase and catalase) may become
overwhelmed leading to lysosomal and mitochondrial
membrane destabilization and ultimately perpetuating
the deleterious effects ofr e d o x - i r o nr e s u l t i n gi n
apoptosis.
This study demonstrated that IV iron preparations
inhibit the survival of the immune cell subpopulations
CD4
+ and CD16
+. The SFG and IS IV iron preparations
were the most injurious to the CD4
+ and the CD16
+
cell subpopulations. It has been shown that the activated
lymphocytes are more susceptible to oxidative stress
mediated apoptosis compared to control populations
[17]. This may offer some insight to explain the reduced
populations of some immune cell subsets because the
immune system in HD patients can be considered to be
constantly “primed” due to interaction with the dialysis
membrane and possibly other inciting factors including
reuse solvents [18]. A limitation to this study is the use
of PBMCs from healthy subjects. Our group and others
have shown that hemodialysis patients with inflamma-
tion generate more oxidative stress biomarkers acutely
after IV iron administration[19,20]. Thus, it could be
speculated that lymphocyte survival after iron-induced
stress would be poorer in PBMCs from uremic hemo-
dialysis patients. It could also be speculated that elimi-
nating the CD4
+ subpopulation could cause the immune
system to become major histocompatibility complex
(MHC) class I restricted. Exogenous antigens like bac-
terial cell wall components are produced outside of a
cell and enter the antigen presenting cells by either
endocytosis or phagocytosis. MHC class II molecules are
expressed on professional antigen presenting cells and
present the exogenous antigen to the CD4
+ population.
If the CD4
+ cell subpopulation were greatly inhibited,
the processing of exogenous antigen presentation
through the MHC class II pathway could also be inhib-
ited. CD16+ monocytes are pro-inflammatory and are
associated with endothelial dysfunction. Transient mod-
est reductions in CD16+ monocyte counts, similar to
the observed reductions in this in vitro study, have been
associated with worse outcomes for cardiovascular end-
points in HD patients[21].
Conclusion
Overall, the smaller molecular weight IV iron-carbohy-
drate complexes produced greater inhibition of some
components of the innate immune system. These data
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the effects of IV iron preparations on the effects of lym-
phocyte subpopulation function and survival as well as
the interaction between immune dysfunction and sus-
ceptibility to certain common pathogens such as Staphy-
lococcal spp. in chronic HD patients.
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